Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of alzheimer's disease

Journal of Alzheimer's Disease

Volumn 40, Issue 3, 2014, Pages 701-712

  Bedse, Gaurav ^a   Romano, Adele ^a   Cianci, Silvia ^a   Lavecchia, Angelo M ^a   Lorenzo, Pace ^d   Elphick, Maurice R ^b   Laferla, Frank M ^c   Vendemiale, Gianluigi ^d   Grillo, Caterina ^a   Altieri, Fabio ^a   Cassano, Tommaso ^d   Gaetani, Silvana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF FOGGIA   (Italy)

Author keywords

3 Tg AD mice; Alzheimer's disease; basolateral amygdala complex; CB1 mRNA; CB1 receptor; endocannabinoid system; hippocampus; prefrontal cortex

Indexed keywords

CANNABINOID 1 RECEPTOR; AMYLOID PRECURSOR PROTEIN; MESSENGER RNA; PRESENILIN 1; PSEN1 PROTEIN, HUMAN; TAU PROTEIN;

AGE; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASOLATERAL AMYGDALA; BRAIN CORTEX; CONTROLLED STUDY; DORSAL HIPPOCAMPUS; GENOTYPE; HIPPOCAMPUS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; POST HOC ANALYSIS; PREFRONTAL CORTEX; PRELIMBIC CORTEX; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; VENTRAL HIPPOCAMPUS; ANIMAL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; TRANSGENIC MOUSE;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; MICE, TRANSGENIC; MUTATION; PRESENILIN-1; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER; TAU PROTEINS;

EID: 84901935478     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131910     Document Type: Article

References (57)

1. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766. (Pubitemid 32267077)
2. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982) Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215, 1237- 1239. (Pubitemid 12106486)
3. Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83, 1017- 1066. (Pubitemid 36828930)
4. Lee JH, Agacinski G, Williams JH, Wilcock GK, Esiri MM, Francis PT, Wong PT, Chen CP, Lai MK (2010) Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. Neurochem Int 57, 985-989.
5. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63, 637- 652. (Pubitemid 24360219)
6. Mulder J, Zilberter M, Pasquare SJ, Alpar A, Schulte G, Ferreira SG, Kofalvi A, Martin-Moreno AM, Keimpema E, Tanila H,Watanabe M, Mackie K, Hortobagyi T, de Ceballos ML, Harkany T (2011) Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain 134, 1041-1060.
7. Kalifa S, Polston EK, Allard JS, Manaye KF (2011) Distribution patterns of cannabinoid CB1 receptors in the hippocampus of APPswe/PS1DeltaE9 double transgenic mice. Brain Res 1376, 94-100.
8. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, Romero J (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23, 11136-11141. (Pubitemid 37548949)
9. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421. (Pubitemid 36937044)
10. Mesulam MM (1999) Neuroplasticity failure in Alzheimer's disease: Bridging the gap between plaques and tangles. Neuron 24, 521-529.
11. Mesulam MM (2000) A plasticity-based theory of the pathogenesis of Alzheimer's disease. Ann N Y Acad Sci 924, 42-52. (Pubitemid 32050182)
12. Oddo S, Caccamo A, Green KN, Liang K, Tran L, Chen Y, Leslie FM, LaFerla FM (2005) Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci U S A 102, 3046- 3051. (Pubitemid 40299913)
13. Cassano T, Serviddio G, Gaetani S, Romano A, Dipasquale P, Cianci S, Bellanti F, Laconca L, Romano AD, Padalino I, LaFerla FM, Nicoletti F, Cuomo V, Vendemiale G (2012) Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease. Neurobiol Aging 33, 1121.e1121-1112.
14. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24, 1063-1070. (Pubitemid 37487883)
15. van Rijn CM, Gaetani S, Santolini I, Badura A, Gabova A, Fu J, Watanabe M, Cuomo V, van Luijtelaar G, Nicoletti F, Ngomba RT (2010)WAG/Rij rats show a reduced expression of CB(1) receptors in thalamic nuclei and respond to the CB(1) receptor agonist, R(+)WIN55,212-2, with a reduced incidence of spike-wave discharges. Epilepsia 51, 1511-1521.
16. Egertova M, Elphick MR (2000) Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 422, 159-171. (Pubitemid 30390161)
17. Bridges D, Rice AS, Egertova M, Elphick MR, Winter J, Michael GJ (2003) Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. Neuroscience 119, 803-812. (Pubitemid 36694807)
18. Monory K, Massa F, Egertova M, Eder M, Blaudzun H,Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave KA, During M, Klugmann M, Wolfel B, Dodt HU, Zieglgansberger W, Wotjak CT,Mackie K, Elphick MR, Marsicano G, Lutz B (2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51, 455-466. (Pubitemid 44209321)
19. Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11, 4213-4225. (Pubitemid 30009252)
20. Egertova M, Cravatt BF, Elphick MR (2003) Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: Evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119, 481-496. (Pubitemid 36588826)
21. Pascal LE, True LD, Campbell DS, Deutsch EW, Risk M, Coleman IM, Eichner LJ, Nelson PS, Liu AY (2008) Correlation of mRNA and protein levels: Cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics 9, 246.
22. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM (2005) Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 25, 8843-8853. (Pubitemid 41384452)
23. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML (2005) Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J Neurosci 25, 1904- 1913. (Pubitemid 40289395)
24. Solas M, Francis PT, Franco R, Ramirez MJ (2013) CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiol Aging 34, 805-808.
25. Psychoyos D, Vinod KY, Cao J, Xie S, Hyson RL, Wlodarczyk B, He W, Cooper TB, Hungund BL, Finnell RH (2012) Cannabinoid receptor 1 signaling in embryo neurodevelopment. Birth Defects Res B Dev Reprod Toxicol 95, 137-150.
26. Romero J, Garcia-Palomero E, Berrendero F, Garcia-Gil L, Hernandez ML, Ramos JA, Fernandez-Ruiz JJ (1997) Atypical location of cannabinoid receptors in white matter areas during rat brain development. Synapse 26, 317-323. (Pubitemid 27240747)
27. Berrendero F, Romero J, Garcia-Gil L, Suarez I, De la Cruz P, Ramos JA, Fernandez-Ruiz JJ (1998) Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats. Biochim Biophys Acta 1407, 205-214. (Pubitemid 29067438)
28. van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D, Micale V, Steardo L, Drago F, Iuvone T, Di Marzo V (2006) Endocannabinoids and beta-amyloidinduced neurotoxicity in vivo: Effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 63, 1410-1424. (Pubitemid 43939021)
29. Tanveer R, Gowran A, Noonan J, Keating SE, Bowie AG, CampbellVA(2012) The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-beta and in the cortex of aged rats. J Biol Chem 287, 34709-34721.
30. Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D (2013) Role of the cannabinoid system in the transit of betaamyloid across the blood-brain barrier. Mol Cell Neurosci 56, 255-262.
31. Arsenault D, Dal-Pan A, Tremblay C, Bennett DA, Guitton MJ, De Koninck Y, Tonegawa S, Calon F (2013) PAK inactivation impairs social recognition in 3xTg-AD Mice without increasing brain deposition of tau and Abeta. J Neurosci 33, 10729-10740.
32. Noristani HN, Meadows RS, Olabarria M, Verkhratsky A, Rodriguez JJ (2011) Increased hippocampal CA1 density of serotonergic terminals in a triple transgenic mouse model of Alzheimer's disease: An ultrastructural study. Cell Death Dis 2, e210.
33. Rodriguez-Ortiz CJ, Hoshino H, Cheng D, Liu-Yescevitz L, Blurton-Jones M, Wolozin B, LaFerla FM, Kitazawa M (2013) Neuronal-specific overexpression of a mutant valosin-containing protein associated with IBMPFD promotes aberrant ubiquitin and TDP-43 accumulation and cognitive dysfunction in transgenic mice. Am J Pathol 183, 504-515.
34. Stumm C, Hiebel C, Hanstein R, Purrio M, Nagel H, Conrad A, Lutz B, Behl C, Clement AB (2013) Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. Neurobiol Aging 34, 2574-2584.
35. Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9- tetrahydrocannabinol, cannabidiol and delta9- tetrahydrocannabivarin. Br J Pharmacol 153, 199-215.
36. Benard G, Massa F, Puente N, Lourenco J, Bellocchio L, Soria-Gomez E, Matias I, Delamarre A, Metna-Laurent M, Cannich A, Hebert-Chatelain E, Mulle C, Ortega-Gutierrez S, Martin-Fontecha M, Klugmann M, Guggenhuber S, Lutz B, Gertsch J, Chaouloff F, Lopez-Rodriguez ML, Grandes P, Rossignol R, Marsicano G (2012) Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat Neurosci 15, 558-564.
37. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD (2009) Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 106, 14670- 14675.
38. Davis KL, Davis BM, Greenwald BS, Mohs RC, Mathe AA, Johns CA, Horvath TB (1986) Cortisol and Alzheimer's disease, I: Basal studies. Am J Psychiatry 143, 300- 305. (Pubitemid 16034087)
39. Masugi F, Ogihara T, Sakaguchi K, Otsuka A, Tsuchiya Y, Morimoto S, Kumahara Y, Saeki S, Nishide M (1989) High plasma levels of cortisol in patients with senile dementia of the Alzheimer's type. Methods Find Exp Clin Pharmacol 11, 707-710. (Pubitemid 20054735)
40. Swanwick GR, Kirby M, Bruce I, Buggy F, Coen RF, Coakley D, Lawlor BA (1998) Hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer's disease: Lack of association between longitudinal and cross-sectional findings. Am J Psychiatry 155, 286-289. (Pubitemid 28074297)
41. Elliott EM, Mattson MP, Vanderklish P, Lynch G, Chang I, Sapolsky RM (1993) Corticosterone exacerbates kainateinduced alterations in hippocampal tau immunoreactivity and spectrin proteolysis in vivo. J Neurochem 61, 57-67. (Pubitemid 23175883)
42. Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM (2006) Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci 26, 9047-9056. (Pubitemid 44319396)
43. Hebda-Bauer EK, Simmons TA, Sugg A, Ural E, Stewart JA, Beals JL, Wei Q, Watson SJ, Akil H (2013) 3xTg-AD mice exhibit an activated central stress axis during early-stage pathology. J Alzheimers Dis 33, 407-422.
44. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ (2004) Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitaryadrenal axis. Endocrinology 145, 5431-5438. (Pubitemid 39564580)
45. Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TT, Gray JM, Hillard CJ, Gorzalka BB, Viau V (2010) Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci U S A 107, 9406-9411.
46. Barna I, Zelena D, Arszovszki AC, Ledent C (2004) The role of endogenous cannabinoids in the hypothalamo-pituitaryadrenal axis regulation: In vivo and in vitro studies in CB1 receptor knockout mice. Life Sci 75, 2959-2970. (Pubitemid 39349260)
47. De Kloet ER, Vreugdenhil E, Oitzl MS, JoelsM(1998) Brain corticosteroid receptor balance in health and disease. Endocr Rev 19, 269-301. (Pubitemid 29117816)
48. Gimenez-Llort L, Blazquez G, Canete T, Johansson B, Oddo S, Tobena A, LaFerla FM, Fernandez-Teruel A (2007) Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: A role for intraneuronal amyloid. Neurosci Biobehav Rev 31, 125-147. (Pubitemid 44895427)
49. Espana J, Gimenez-Llort L, Valero J, Minano A, Rabano A, Rodriguez-Alvarez J, LaFerla FM, SauraCA(2010) Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol Psychiatry 67, 513-521.
50. Cota D, Steiner MA, Marsicano G, Cervino C, Herman JP, Grubler Y, Stalla J, Pasquali R, Lutz B, Stalla GK, Pagotto U (2007) Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 148, 1574-1581. (Pubitemid 46457104)
51. Steiner MA, Marsicano G, Wotjak CT, Lutz B (2008) Conditional cannabinoid receptor type 1 mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress responses. Psychoneuroendocrinology 33, 1165-1170.
52. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16, 1395-1398. (Pubitemid 35340861)
53. Maccarrone M, Valverde O, Barbaccia ML, Castane A, Maldonado R, Ledent C, Parmentier M, Finazzi-Agro A (2002) Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: Correlation with behaviour. Eur J Neurosci 15, 1178-1186. (Pubitemid 35463618)
54. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002) Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159, 379-387. (Pubitemid 34143362)
55. Aso E, Ozaita A, Serra MA, Maldonado R (2011) Genes differentially expressed in CB1 knockout mice: Involvement in the depressive-like phenotype. Eur Neuropsychopharmacol 21, 11-22.
56. Valverde O, Torrens M (2012) CB1 receptor-deficient mice as a model for depression. Neuroscience 204, 193-206.
57. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45, 675-688. (Pubitemid 40320703)